Article
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Medicina clinica - 4 Aug 2013
Marcé Silvia, Zamora Lurdes, Cabezón Marta, Xicoy Blanca, Boqué Concha, Fernández Cristalina, Grau Javier, Navarro José-Tomás, Fernández de Sevilla Alberto, Ribera Josep-Maria, Feliu Evarist, Millá Fuensanta
Abstract excerpt
BACKGROUND AND OBJECTIVES: Tyrosine kinase inhibitors (TKI) have improved the management of patients with chronic myeloid leukemia (CML). However, a significant proportion of patients do not achieve the optimal response or are resistant to TKI. ABL kinase domain mutations have been extensively implicated in the pathogenesis of TKI resistance. Treatment with second-generation TKI has produced high rates of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.